JavaScript is disabled. Please enable to continue!
Mobile search icon
Media Centre >> Press Releases 2015 >> 2015-12-03

Eurofins expands into hygiene testing in hospitals with the acquisition of Biotech-Germande

Sidebar Image

Thursday, December 3, 2015

Eurofins Scientific (EUFI.PA), the global leader in bioanalytical testing of food, pharmaceuticals and the environment, announces that it has signed an agreement to acquire Biotech-Germande SAS (BG), one of the leading players in the environmental clinical testing and hospital hygiene market, as well as in medical device evaluation in France. 

Located in Marseille, BG employs 40 staff, and has established a strong reputation over the last 15 years, as a reference in healthcare and hospital hygiene. The company conducts testing of water, air, surfaces and endoscopes in hospitals and healthcare facilities, as well as evaluation of medical devices for manufacturers. BG has seen, and expects to continue to post, strong growth driven primarily by hospitals outsourcing mandatory infectious controls, and increasingly stringent regulations for independent testing of medical devices.

The acquisition complements Eurofins' growing footprint in the testing market for the healthcare sector in France, and allows the Group to create a more compelling portfolio of services for hospitals and other healthcare facilities served by Bioaccess and Biomnis. In return, BG should gain access to Eurofins' infrastructure, including the Group's complete testing portfolio for hospitals and drug & medical device manufacturers, and could leverage Eurofins' extensive network to further accelerate growth. Eurofins' existing footprint in water testing, as well as the Group's unparalleled capabilities in microbiology, should allow BG to expand its market reach or accelerate share gains in its existing markets.

Comment from Dr. Gilles Martin, Eurofins CEO: "Biotech-Germande strengthens Eurofins' service offering to hospitals in a key area for patients' safety, and reinforces our growing footprint in medical device testing. We look forward to strengthening BG's position in its market by providing them access to the Group's complete range of capabilities, as well as client base."

For more information, please visit www.eurofins.com or contact:

Eurofins Investor Relations

Phone: +32 2 766 1620

E-mail: ir@eurofins.com

Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food, environment and pharmaceutical products testing. It is also one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.

With 20,000 staff in around 200 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.